Twenty-two people with PTSD, and a large drop with no control
What they did
Twenty-two people with post-traumatic stress disorder received a single 25mg dose of psilocybin across multiple sites, with safety and tolerability as the primary aim.
What they found
No serious adverse events occurred. Mean scores on the standard PTSD assessment fell by 29.9 points at week four and 29.5 points at week twelve. Headache affected half the group and nausea affected around a third.
Worth knowing
Open-label with nobody randomised and nothing to compare against, in a condition with a well-documented large placebo response. Read this as a safety result with an encouraging side note.
McGowan et al. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder. Journal of Psychopharmacology, 2026.
Read the sourceKeep reading
eating disordersTwenty-one women with anorexia, and symptoms that improved for a yearOCDOne small trial is the entire case for psilocybin and OCDcluster headacheCluster headaches dropped on psilocybin, but not significantlyWe include the trials that missed their endpoints alongside the ones that hit. A shelf that only holds good news is a marketing page, not a library.
For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.